Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for July, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- How to Invest in QE's Twilight
- RTI: Fed Keeps QE Pace Unchanged
- ETFs on the Move After Bernanke's Press Conference
- AWS 6/20: Bernanke Shows His Hand
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- Your Next Stock Should Be Making New Highs
- PFP 6/20: I Am FED UP!
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.40% |
| SUPPORTCOM I | SPRT | 3.75% |
| UNISYS CORP | UIS | 3.31% |
| SHORETEL INC | SHOR | 3.22% |
| GREEN MOUNTA | GMCR | 3.13% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Celgene Corporation (CELG - Analyst Report) recently announced positive top-line results on its candidate apremilast from a phase III study (PALACE-1: n~500), which is evaluating patients suffering from psoriatic arthritis at 20 mg and 30 mg dosages. We note that psoriatic arthritis refers to a painful, chronic inflammatory disease, associated with psoriasis (a skin-related disorder).
Top-line results from the randomized, placebo-controlled, pivotal study revealed that patients treated with apremilast achieved the primary endpoint defined by the American College of Rheumatology criteria for 20% improvement (ACR20) compared to baseline at week 16.
Top-line data also revealed that treatment with apremilast resulted in significant improvements in arthritis-related endpoints (including ACR50 and ACR70) through week 24 across the evaluated dosages.
Moreover, apremilast also resulted in improvements in various measures of physical function. Furthermore, treatment with the candidate was found to be safe. Celgene stated that the extension phase of the study will remain blinded until all patients have completed week 52.
We note that apart from the PALACE-1 study, the PALACE program consists of two more phase III studies (PALACE 2 and PALACE 3). Celgene intends to present top-line data from both studies in the third quarter of 2012. Celgene intends to seek US approval for apremilast in the psoriatic arthritis indication based on data from the PALACE program in the first half of 2013.
Celgene is also evaluating apremilast in patients suffering from moderate-to-severe psoriasis. Data from two ongoing phase III studies (ESTEEM 1 and 2) evaluating apremilast in patients suffering from moderate-to-severe psoriasis are expected by year end. Celgene intends to seek US approval for apremilast in the psoriasis indication in the second half of 2013.
European approval is expected to be sought in the second half of 2013. Other indications for which apremilast is being studied include rheumatoid arthritis and ankylosing spondylitis. Successful development of apremilast would boost the stock. Apremilast, on approval, would compete with drugs such as Amgen/Pfizer’s (AMGN - Analyst Report)/(PFE - Analyst Report) Enbrel in the market for inflammatory diseases.
Our Recommendation
We currently have a Neutral recommendation on Celgene. The stock carries a Zacks #3 Rank (Hold rating) in the short-run.
Get the full Analyst Report on CELG - FREE
Get the full Analyst Report on PFE - FREE
Get the full Analyst Report on AMGN - FREE